Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Characterization of Variable MARrcha's Diary Variables as a Useful Measure

6 maggio 2019 aggiornato da: Ferran Morell

Characterization of Variable MARrcha's Diary Variables as a Useful Measure of Physical Activity in Patients With Physical COPD in Patients With COPD

Validate a simple clinical tool to evaluate physical activity (the question "How many minutes does it walk per day?" Or equivalent), compared to the rest of the collected physical activity data (PROactive questionnaire and objective physical activity data by means of an accelerometer record) in patients with COPD.

Panoramica dello studio

Stato

Sconosciuto

Descrizione dettagliata

Observational, national and multicenter epidemiological study in adult patients with COPD that will take place in the consultations of specialists in pneumology under conditions of usual clinical practice and that will be developed in two visits per patient.

Tipo di studio

Osservativo

Iscrizione (Anticipato)

10

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Cataluña
      • Barcelona, Cataluña, Spagna, 08008
        • Reclutamento
        • FUCAP
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Francisco Ortega
        • Investigatore principale:
          • Cristina Martínez
        • Investigatore principale:
          • Marc Miravitlles
        • Investigatore principale:
          • Francisco García-Río
        • Investigatore principale:
          • Pilar Carmen Cebollero
        • Investigatore principale:
          • Cristóbal Esteban
        • Investigatore principale:
          • Patricia Sobradillo
        • Investigatore principale:
          • Ernesto Centeno
        • Investigatore principale:
          • María Inés Carrascosa
        • Investigatore principale:
          • Juan José Soler-Cataluña

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

40 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The population under study will be constituted by adult patients diagnosed with COPD.

To avoid selection biases, each participating researcher will include in the study the first 10 patients who come to a pulmonology clinic with a clinical diagnosis of COPD and who meet the selection criteria.

Descrizione

Inclusion Criteria:

Adult patients, ≥ 40 years.

  • Patients diagnosed with COPD according to the GOLD criteria: FEV1 / FVC postbronchodilator <0.70 in a spirometry performed in the last 12 months.
  • Smokers or ex-smokers of ≥10 pack-years.
  • Patients with a minimum age in the diagnosis of COPD of at least 6 months.
  • Patients who accept their participation in the study and who have given their informed consent (IC) in writing to participate in it.

Exclusion Criteria:

  • Patients whose clinical history data are not available.
  • Patients unable to understand the study questionnaires.
  • Patients with physical limitation (not caused by the respiratory disease, eg disability, orthopedic limitation, etc.) and / or psychic that prevents the proper conduct of the study.
  • Patients who present a moderate or severe exacerbation of COPD in the month prior to inclusion.
  • Patients with other chronic respiratory diseases other than COPD (such as cystic fibrosis, bronchiectasis of origin other than COPD, neoplasia, pneumonia).
  • Patients with serious cardiovascular or neurological diseases.
  • Hospital admission for any reason in the month prior to inclusion.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Minutes of daily walking
Lasso di tempo: During the 7 days that the device has.

For such effects, the level of physical activity will be determined through a unique question, formulated in 5 different ways, which aims to collect the minutes of physical activity or daily walking minutes. The one that best fits the objective of the study will be selected.

The questions that will be asked will be:

  1. How many minutes do you walk per day, on average?
  2. How many minutes do you walk briskly a day, on average?
  3. How many minutes do you walk outside the home on average?
  4. How many minutes do you spend doing physical activity a day, on average?
  5. How many minutes per day do you engage in moderate to intense physical activity, such as brisk walking, cycling, working in the garden, swimming, dancing, etc., on average?
During the 7 days that the device has.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Date of inclusion in the study
Lasso di tempo: day 9
[day-month-year]
day 9
Age
Lasso di tempo: day 9
[date of birth, day-month-year]
day 9
Sex
Lasso di tempo: day 9
[male / female]
day 9
Size
Lasso di tempo: day 9
[cm]
day 9
Weight
Lasso di tempo: day 9
[kg]
day 9
Body Mass Index
Lasso di tempo: day 9
(BMI) [kg / m2]
day 9
Marital Status
Lasso di tempo: day 9
[single / married / separated / divorced / widowed]
day 9
Family situation
Lasso di tempo: day 9

Coexistence situation [only (a) / accompanied)

  • Has children? [if not]
  • If yes, how many children? [and ages for each child]
  • Does any child live in the family home? [if not]
  • Number of children in the family home [ages of these children]
  • Do you have grandchildren? [if not]
  • If yes, how many grandchildren? [and ages for each grandchild]
  • Care for your grandchildren on a regular basis? [if not]
  • Age of each grandchild in care
  • Frequency with which she takes care of grandchildren [times / week]
  • Do you have dog / s? [if not. If yes, specify how many]
day 9
Place of residence
Lasso di tempo: day 9
[house / flat / others, specify]
day 9
Academic training
Lasso di tempo: day 9
[without studies, primary, secondary, university studies]
day 9
Employment status
Lasso di tempo: day 9
[self-employed / self-employed / unemployed / retired (a) / household tasks / other, specify]
day 9
Socioeconomic level
Lasso di tempo: day 9
family income 15000€/15000€-25000€/25000€-30000€/>30000€
day 9
Smoking
Lasso di tempo: day 9

[yes / ex]

  • If yes, how many cigarettes / day now? How many packages / year? How many years of current smoking?
  • In the case of an ex-smoker, how many cigarettes / day did he smoke? How many packages / year did he smoke? How many years of previous smoking? How many years / months without smoking until the start of the study?
day 9
Date
Lasso di tempo: day 9
[day-month-year]
day 9
Description of instruments and measures
Lasso di tempo: day 9

Spirometry is a test of lung function (flow and capacity) that evaluates the amount of air through exhalation. The forced spirometry, in particular, is based on making the patient after a maximum inspiration exhale all the air, in the shortest time possible.

[forced expiratory volume the first second (FEV1) in milliliters / forced vital capacity (FVC) in milliliters / FEV1 / FVC ratio (FEV1%)

day 9
FEV1
Lasso di tempo: day 9
it is a measure of flow and is expressed in milliliters and is the maximum volume exhaled in the first second of a forced expiration. Its normal value is> 80% of the theoretical value.
day 9
FVC
Lasso di tempo: day 9
it is a measurement of capacity that is expressed in milliliters and is the maximum volume of exhaled air with the maximum possible effort, based on the total volume that the patient expels from maximum inspiration to maximum expiration. Its normal value is> 80% of the theoretical value.
day 9
FEV1%
Lasso di tempo: day 9
it is indicative of the percentage of the total volume expired during the first second. Its normal value is> 70-75% of the theoretical value.
day 9
Phenotype of COPD
Lasso di tempo: day 9
[non-exacerbator / mixed COPD-asthma / exacerbation with emphysema /exacerbator with chronic bronchitis]
day 9
Non-pharmacological treatment
Lasso di tempo: day 9
[smoking cessation / rehabilitation program / oxygen therapy / others, specify]
day 9
Number and scope of treatment of exacerbations suffered in the last year
Lasso di tempo: day 9
[ambulatory / hospital]
day 9
Date of the last moderate-severe exacerbation.
Lasso di tempo: day 9
[day-month-year]
day 9
Scales, questionnaires and indexes
Lasso di tempo: day 9
  • IMC
  • FEV1% Dyspnea (from the modified MRC scale)
  • Distance collected in the 6MW [meters]
  • Serious exacerbations in the last 12 months (only visits to hospital emergencies or admissions are included) [number of exacerbations]
  • Determination of the prognostic severity according to BODEX data [three levels: I (mild of 0-2 points), II (moderate, 3-4 points), III (severe, ≥5 points)].
  • COTE comorbidity index, calculated according to 10 comorbidities to be assessed with variable scores, between 1 and 6 points [see Annex 9 for the complete list of comorbidities to be analyzed]
day 9
Spirometry
Lasso di tempo: day 9
  • FEV1: is a measure of flow and is expressed in milliliters and is the maximum volume expired in the first second of a forced expiration. Its normal value is> 80% of the theoretical value.
  • FVC: is a measure of capacity that is expressed in milliliters and is the maximum volume of exhaled air with the maximum possible effort, based on the total volume that the patient expels from maximum inspiration to maximum expiration. Its normal value is> 80% of the theoretical value.
  • Ratio FEV1 / FVC x 100 (FEV1%): it is indicative of the percentage of the total expired volume during the first second. Its normal value is> 70-75% of the theoretical value.
day 9
BODE and BODEX Index (Annex 8)
Lasso di tempo: day 9
  • The BODE index integrates the BMI, the FEV1, the degree of dyspnea (through the data of the modified MRC scale) and the exercise capacity evaluated by means of a 6-minute walk test. The scores of each variable range from 0 to 3 (range 0-10). An increase in one point of the BODE index is associated with a 34% increase in mortality from all causes and 62% in mortality from respiratory causes.
  • The BODEX index takes into account the number of severe exacerbations (visits to hospital emergencies and admissions) instead of the walking test. The scores for each variable range from 0 to 3 (range 0-9). If the BODEx index is ≥ 5 points, the exercise test will be taken into account to determine the level of severity. Three levels of prognostic severity of COPD will be established: I (mild of 0-2 points), II (moderate, 3-4 points), III (severe, ≥5 points).
day 9
COTE comorbidity index (annex 9)
Lasso di tempo: day 9
The COTE index (Divo et al., 2012) describes 10 comorbidities: cancer (lung, esophagus, pancreas and breast) (6 points), other cancers (2 points), anxiety (in women, 6 points), liver cirrhosis (2 points), atrial fibrillation (2 points), diabetes with neuropathy (2 points), pulmonary fibrosis (2 points), congestive heart failure (1 point), gastroduodenal ulcer (1 point) and coronary disease (1 point) (range) 0-25). A score ≥ 4 increases more than 2 times the expected risk of death.
day 9
Charlson comorbidity index (InCC) (Annex 10)
Lasso di tempo: day 9
The Charlson comorbidity index (Charlson et al., 1987) is a 10-year survival assessment system, depending on the age of the patient being evaluated and the comorbidities of the subject. In addition to age, it consists of 19 items, which if present, have been found to influence the patient's life expectancy. Each item has a weight in the index, which can be 1, 2, 3 and 6. The age ranges are also scored from 0 to 5.
day 9
HADS questionnaire (Annex 11)
Lasso di tempo: day 9
It is a scale that evaluates patients' anxiety and depression status (Zigmond & Snaith, 1983). One of its main attractions is that it suppresses somatic symptoms so that it can be evaluated independently of the underlying somatic disease. It consists of 14 items on a Likert scale of 4 points (range 0 - 3) to assess anxiety and depression (7 items for each). The total score is the sum of the 14 items (range 0 - 42), and for each subscale the score is the sum of the 7 items (range 0 - 21). It is considered that between 0 and 7 it does not indicate case, between 8 and 10 it would be a doubtful case and the scores superior to 11 are, probably, cases in each one of the subscales.
day 9
CAT Scale (Annex 12)
Lasso di tempo: day 9
The CAT scale (Jones et al., 2009) measures the impact that COPD is having on the well-being and daily life of patients. It consists of 8 items (cough, sputum, tightness in the chest, shortness of breath climbing slopes / stairs, limitation of activity in the home, confidence to leave home, sleep and energy). Each item is valued on a scale of 6 points with different formats semantically (from 0 to 5), with a total score from 0 to 40. A score between 0-10 would be indicative of a low impact of the disease.
day 9
Modified MRC scale (Annex 13)
Lasso di tempo: day 9
The modified MRC scale (Mahler & Wells, 1988) uses a very simple grading system to obtain the degree of dyspnea of the patient. This scale does not define the sensation of drowning per se, but it shows the degree of alteration that said drowning exerts on a day-to-day basis. It consists of 5 degrees of physical activity that provokes dyspnea that ranges from 0 (no type of exercise is capable of inducing dyspnea) and 4 (dyspnea prevents the patient from leaving the house or doing activities such as dressing or grooming). A higher score would be indicative of a greater degree of functional limitation.
day 9
PROactive questionnaire (Annex 14)
Lasso di tempo: day 9
This questionnaire about physical activity is a hybrid tool that combines results perceived by patients (PRO) and given physical activity objectives that come from the accelerometer (Gimeno-Santos et al., 2015). The version for clinical visit (Clinical visit PROactive PRO) will be used, which gathers the experiences of physical activity of the patients in the last 7 days. It consists of 12 questions and 2 variables of the accelerometer (14 items in total), with options on a Likert scale of 0 to 4 points, and with a score that ranges between 0 and 56 points.
day 9
Accelerometer (Annex 15)
Lasso di tempo: from day 2 to 8
The accelerometer is a motion sensor that uses a pinzoelectric transducer to detect acceleration movements in any of the 3 space dimensions (antero-posterior, medial-lateral, and longitudinal). Continuous monitoring of the actual physical activity of each patient will be obtained through a triaxial accelerometer (Dynaport® MoveMonitor) for a week. The accelerometer will be placed on all participants on the day of the IC signature. The device will be programmed to start the measurement on the day following V0 (day 2). The patient will be instructed to carry the device 24 hours a day for the next 7 days (day 2-8).
from day 2 to 8
Proof of the march (PM6M) (Annex 16)
Lasso di tempo: day 9
It is a physical activity test to evaluate the effort capacity, being very simple and easy to perform, with the use of very little equipment (Holland et al., 2014, Singh et al., 2014). In this case, the maximum distance in meters that the patient travels in 6 minutes will be evaluated. Due to the learning factor demonstrated in this test, 2 tests will be carried out and the test in which the patient reached the greatest distance will be taken into account in the analysis.
day 9
Questionnaire on motivation to perform physical activity.
Lasso di tempo: day 9
This is the translation into Spanish of the questionnaire developed by Danilack et al, 2014 It consists of 4 domains (motivation, confidence, physical environment and social support) For the general reasons of motivation and trust, the subjects were asked: In general, how motivated are you to walk every day? And How confident do you feel you can walk every day? with responses on a Likert scale from 1 to 10, where the highest scores reflect greater motivation and confidence. In addition, motivation and confidence were characterized to evaluate the reasons for walking and the confidence to exercise in different situations, including health reasons, bad weather, low energy, lack of time and fear of injury.
day 9

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Ferran Morell, Fundacio Catalana de Pneumologia

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 marzo 2019

Completamento primario (Anticipato)

1 dicembre 2019

Completamento dello studio (Anticipato)

1 aprile 2020

Date di iscrizione allo studio

Primo inviato

15 aprile 2019

Primo inviato che soddisfa i criteri di controllo qualità

6 maggio 2019

Primo Inserito (Effettivo)

8 maggio 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 maggio 2019

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 maggio 2019

Ultimo verificato

1 maggio 2019

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • FUC-EPO-2018-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Descrizione del piano IPD

Pending confirmation with sponsor

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

3
Sottoscrivi